As a fungal lectin that binds specifically to the cancer-associated glycan and inhibits the growth of human breast cancer cells but has substantially less effect on normal epithelial cells, SRL has the potential to be developed as an anti-cancer agent. Here, SRL is linked to breast carcinoma.